Fresh analysis reveals that patients who come off new slimming jabs like Wegovy and Mounjaro may regain reduced body mass at a significantly accelerated pace than those who halt conventional diet and exercise programs.
Published data in a leading medical journal shows that while obese people often shed about a fifth of their body weight while undergoing treatment, the mass returns at an average rate of nearly a kilo each month once they quit.
"Users buying such drugs must be aware of the risk of fast weight regain when the therapy ends," warns expert Dr. Susan Jebb.
That rate of regain means a return to original weight in about 18 months.
Analyzing Approaches
The research, which looked at 37 of trials involving over 9,000 of participants, contrasted the effects of GLP-1 agonists with other pills.
The team emphasize that people who lose weight through lifestyle changes alone generally experience a slower weight regain—perhaps 100 grams monthly—after stopping.
Explaining the Quick Regain
Doctors suggest the mechanism of the injections explains the heightened rebound.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Long-term administration of the hormone concentrations far above than the body's typical production could lead to the body to produce less of its own natural hormone, and could reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this hormone supplement leads to appetite is unsuppressed, making excessive eating much more probable."
A Lifelong Disease?
Medical guidelines advise the injections for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Many experts say that, due to the high risk of relapse, the therapy is often life-long.
This opinion is reinforced by drug manufacturers, who say that the findings "underscore the chronic character of excess weight," akin to managing diseases like high blood pressure.
User Testimonies
People who have discontinued the jabs report a powerful return of cravings.
"It felt as if something activating and you become extremely hungry," described a patient.
This challenge is exacerbated if individuals have not developed sustainable lifestyle or habit modifications during therapy.
Significant Adoption
Survey data indicate that millions of people in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Adoption is greater among females compared to males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent solution and long-term success hinges on combined lifestyle management.
